ClinicalTrials.gg
CompletedNCT01686555Updated Nov 20, 2017

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ABT-199 in Female Patients With Systemic Lupus Erythematosus (SLE)

A Phase 1 interventional study of ABT-199 and Placebo in Lupus Erythematosus, sponsored by AbbVie (prior sponsor, Abbott). Completed at 15 sites in 4 countries. Open to female participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2017-11-20.

Sponsored by AbbVie (prior sponsor, Abbott) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
97
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
Female
01

Study summary

To assess the safety, tolerability and pharmacokinetics of ABT-199 in female subjects with Systemic Lupus Erythematosus.

Read the detailed description

This is a phase 1, randomized, double-blind, placebo-controlled, single-and multiple ascending dose study. Up to eighty-eight subjects with Systemic Lupus Erythematosus will be selected to participate. Subjects will be randomized to receive either ABT-199 or placebo. Subjects will be administered ABT-199/placebo as a single dose or up to 14 days as multiple doses.

02

Conditions studied

  • Lupus Erythematosus
03

In context

Lead sponsor

AbbVie (prior sponsor, Abbott) is the lead sponsor of 223 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of systemic lupus erythematosus for at least 6 months.
  • Documentation of at least one of the following: ANA titer >= 1:160 or positive anti-dsDNA antibodies.
  • Stable systemic lupus erythematosus medication regimen.
  • Other than systemic lupus erythematosus, subject should be in general good health.

Exclusion criteria

Exclusion Criteria:

  • Male.
  • Drug-induced or highly active systemic lupus erythematosus.
  • Significant disease other than lupus.
  • Significant, uncontrolled or unstable disease in any organ.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
97 participants (actual)

Study arms

  • Experimental
    Single Dose

    Subjects enrolled in the Single Ascending Dose (SAD) part of the study will receive a single dose of study drug or placebo. (Groups 1, 2, 3, 4, 5 and 6).

    Drug: ABT-199 · Other: Placebo

  • Experimental
    Multiple Dose

    Subjects enrolled in the Multiple Ascending Dose (MAD) part of the study will receive multiple doses of study drug or placebo. (Groups 7, 8, 9, 10 and 11)

    Drug: ABT-199 · Other: Placebo

Interventions

  • Tablet

  • OtherPlacebo

    Tablet

06

What researchers measure

Primary outcomes

  1. Number of participants with Adverse Events

    Collect all adverse events at each visit

    Time frame: From first dose of ABT-199 until 28 days after single dose of ABT-199 and until 21 days after the last multiple dose of ABT-199

  2. Physical Exam including vital signs

    Blood pressure, heart rate and body temperature

    Time frame: Prior to the first dose of ABT-199 until 28 days after single dose of ABT-199 and until 21 days after the last multiple dose of ABT-199

  3. Clinical Lab Testing

    Hematology, Chemistry, and Urinalysis

    Time frame: Prior to the first dose of ABT-199 until 28 days after single dose of ABT-199 and until 21 days after the last multiple dose of ABT-199

  4. Electrocardiogram (ECG) Measurements

    ECGs done in triplicate

    Time frame: For 24 hours after a single dose of ABT-199 and up to 24 hours after the seventh dose of multiple doses of ABT-199

  5. Maximum observed serum concentration (Cmax) of ABT-199

    Cmax

    Time frame: For 72 hours after a single dose of ABT-199 and for 24 hours after the seventh dose of multiple doses of ABT-199

  6. Time to Cmax (Tmax) of ABT-199

    Time to Cmax

    Time frame: For 72 hours after a single dose of ABT-199 and for 24 hours after the seventh dose of multiple doses of ABT-199

  7. The area under the time curve (AUC) of ABT-199

    the area under the exposure-time curve of ABT-199 extrapolated to infinite time for single doses and up to 24 hrs for multiple doses of ABT-199

    Time frame: For 72 hours after a single dose of ABT-199 and for 24 hours after the seventh dose of multiple doses of ABT-199

  8. The terminal phase elimination rate constant and the terminal elimination half-life (t1/2) of ABT-199

    The terminal phase elimination rate constant and the terminal elimination half-life (t1/2) of ABT-199

    Time frame: For 72 hours after a single dose of ABT-199

Secondary outcomes

  1. Measurement of lymphocyte depletion and recovery

    explore pharmacokinetic/pharmacodynamic relationship

    Time frame: Prior to the first dose of ABT-199 until 28 days after single dose of ABT-199 and until 21 days after the last multiple dose of ABT-199

07

Study locations

15 sites
  • Site Reference ID/Investigator# 89694
    Clearwater, Florida 33765, United States
  • Site Reference ID/Investigator# 131720
    DeBary, Florida 32713, United States
  • Site Reference ID/Investigator# 124116
    Miami Lakes, Florida 33016, United States
  • Site Reference ID/Investigator# 118637
    Miami, Florida 33136, United States
  • Site Reference ID/Investigator# 89693
    Orlando, Florida 32806, United States
  • Site Reference ID/Investigator# 78256
    Overland Park, Kansas 66212, United States
  • Site Reference ID/Investigator# 129826
    Rochester, Minnesota 55905, United States
  • Site Reference ID/Investigator# 89773
    Manhasset, New York 11030, United States
  • Site Reference ID/Investigator# 78254
    Duncansville, Pennsylvania 16635, United States
  • Site Reference ID/Investigator# 123335
    Dallas, Texas 75231, United States
  • Site Reference ID/Investigator# 78253
    Dallas, Texas 75231, United States
  • Site Reference ID/Investigator# 107896
    Berlin, 10117, Germany
  • Site Reference ID/Investigator# 116395
    Distrito Federal, CP 14050, Mexico
  • Site Reference ID/Investigator# 112555
    Monterrey, C.P. 64000, Mexico
  • Site Reference ID/Investigator# 132009
    San Juan, 00909-3004, Puerto Rico
08

References and documents

Publications

  • Lu P, Fleischmann R, Curtis C, Ignatenko S, Clarke SH, Desai M, Wong SL, Grebe KM, Black K, Zeng J, Stolzenbach J, Medema JK. Safety and pharmacodynamics of venetoclax (ABT-199) in a randomized single and multiple ascending dose study in women with systemic lupus erythematosus. Lupus. 2018 Feb;27(2):290-302. doi: 10.1177/0961203317719334. Epub 2017 Jul 10. PubMed 28691866 ↗
  • Nader A, Minocha M, Othman AA. Exposure-Response Analyses of the Effects of Venetoclax, a Selective BCL-2 Inhibitor, on B-Lymphocyte and Total Lymphocyte Counts in Women with Systemic Lupus Erythematosus. Clin Pharmacokinet. 2020 Mar;59(3):335-347. doi: 10.1007/s40262-019-00818-5. PubMed 31541431 ↗
  • Minocha M, Zeng J, Medema JK, Othman AA. Pharmacokinetics of the B-Cell Lymphoma 2 (Bcl-2) Inhibitor Venetoclax in Female Subjects with Systemic Lupus Erythematosus. Clin Pharmacokinet. 2018 Sep;57(9):1185-1198. doi: 10.1007/s40262-017-0625-2. PubMed 29333561 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2012, a primary completion of Jun 2015 and a completion of Jun 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 13, 2012
First posted
Sep 18, 2012
Start
Nov 2012
Primary completionActual
Jun 2015
CompletionActual
Jun 2015
Last update
Nov 20, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 20, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01686555
Responsible party
Sponsor
First posted
Sep 18, 2012
Start date
Nov 2012
Primary completion
Jun 2015
Completion
Jun 2015
Last update
Nov 20, 2017

Study contacts

Peng Lu, MD
study director · AbbVie

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Venetoclax

Start the discussion